Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus

Ji Hyun Kim

doi:10.4093/dmj.2015.39.4.304

Articles

Page Path: HOME > Diabetes Metab J > Volume 39(4); 2015 > Article

Editorial Others Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus: Ji Hyun Kim; Diabetes & Metabolism Journal 2015;39(4):304-306.
DOI: https://doi.org/10.4093/dmj.2015.39.4.304
Published online: August 17, 2015

3,689 Views
44 Download
3 Web of Science
4 Crossref
4 Scopus

Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Corresponding author: Ji Hyun Kim. Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Paul's Hospital, College of Medicine, The Catholic University of Korea, 180 Wangsan-ro, Dongdaemun-gu, Seoul 02559, Korea. kjhyun@catholic.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

Full Article

Download PDF

NOTES
REFERENCES
About this article

Recently, the use of dipeptidyl peptidase-4 (DPP4) inhibitors in the management of type 2 diabetes mellitus (T2DM) has been widespread. This class drug control the fasting and postprandial glucose (PPG) levels in a glucose dependent manner. By slowing incretin degradation, DPP4 inhibitors increase the levels of active glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, and thereby stimulate insulin secretion and suppress glucagon release based on blood glucose level [1]. Sitagliptin, a highly selective DPP4 inhibitor, also has been demonstrated to control glucose levels through the similar mode of action [2].

Since several studies have reported that DPP4 inhibitors exhibit a better glucose lowering efficacy in Asian populations than in non-Asians with T2DM [3], sitagliptin may be one of appropriate treatment for T2DM in Asian patients. Most studies showed that sitagliptin treatment leads to significant improvements in β-cell function [4]. In Asian patients, β-cell dysfunction is major pathophysiology of T2DM. Furthermore, insulin secretory defect is more prominent in Asian than in Caucasian patients [5]. The changes of plasma insulin levels and glucagon levels during oral glucose tolerance test (OGTT) could be differed by ethnic groups and could partly elucidate the response of DPP4 inhibitors.

In Western patients with T2DM, there were many studies evaluating the effect of DPP4 inhibitors on blood insulin and glucagon levels. Herman et al. [1] showed that single doses of sitagliptin increased insulin (21% to 22%) and C-peptide (13% to 21%) levels, reduced plasma glucagon levels (7% to 14%), and reduced glycemic excursion following an OGTT. In short-term clinical study of 2 weeks, sitagliptin reduced mean postprandial plasma glucagon concentration relative to baseline [6]. Relatively long-term clinical studies also evaluated markers of β-cell function such as homeostasis model of assessment of β-cell function (HOMA-β), fasting proinsulin-to-insulin ratio, fasting insulin secretion and the insulinogenic index, an index of early insulin release in response to a meal [7]. It has been reported that sitagliptin significantly improve these indices related to β-cell function in patients with T2DM [8 9 10].

However, clinical studies aimed to evaluate β-cell function by DPP4 inhibitor treatment in Asian patients are uncommon. In a couple of studies conducted in China, India, and Korea, sitagliptin did lead to significant improvement of indices of β-cell function, 2-hour postprandial insulin, C-peptide and the insulinogenic index [11] and saxagliptin increased HOMA-β assessment [12]. In other study, which was to evaluate the effects of sitagliptin in Japanese patients with T2DM, 3-day treatment with sitagliptin showed significant decrease of PPG and the area under the curve_{0 to 2 hour} for glucagon throughout the meal tolerance test [13]. Moreover, it improved the insulinogenic index and suppressed glucagon responses significantly for 12 weeks [14 15].

There are few data available to assess the effect of DPP4 inhibitors on insulin or glucagon in Korean patients with T2DM. Considering already proven the stronger effect of DPP4 inhibitors on glycosylated hemoglobin (HbA1c) reduction in Asians [3 14], we can expect that a marked change of insulin or glucagon levels after the use of DPP4 inhibitors in Korean patients with reduced pancreatic insulin secretion. A subset of study on Asian type 2 diabetic patients showed that the treatment with sitagliptin for 18 weeks significantly reduced HbA1c by 1.4% in Korean compared with placebo. Significant improvements of indices of β-cell function were also observed in this study [11]. Another DPP4 inhibitor, gemigliptin had been reported to significantly improve insulin secretory function, as assessed using HOMA-β, proinsulin/insulin ratio and the insulinogenic index with 2-hour post-OGTT insulin and C-peptide levels in Korean patients with T2DM, as well [16].

In this issue, Yang et al. [17] investigated the effect of sitagliptin on plasma glucose, insulin and glucagon responses in Korean patients with T2DM. The insulinogenic index increased after treatment with sitagliptin for 6 months, especially in patients with higher body mass index (BMI) and higher HbA1c level. Although no significant differences in the levels of glucagon and glucagon/insulin ratio were observed, there was a significant reduction in the percentile change of glucagon/insulin ratio. In this study, indices of β-cell function were measured during a 75-g OGTT and the 3-day washout period was used to obviate any acute effect of sitagliptin on β-cell insulin or α-cell glucagon secretion during testing. As a result, they could investigate the long-term effect of sitagliptin without any acute effects of the study drugs, so these findings were novel. In addition, it was interesting that the insulinogenic index significantly increased especially in subgroup of the higher BMI group. Most Korean and Japanese oriented studies reported that sitagliptin is expected to be more effective in patients with lower baseline BMI [18 19], because BMI is highly correlated with insulin sensitivity. On the contrary, other conflicting data suggested that the DPP4 inhibitors were also effective for glycemic control in patients with a high BMI. It was speculated that a high BMI might reflect sustained insulin secretory function [20]. More clinical studies are needed to find accurate predictive parameters for the therapeutic efficacy of DPP4 inhibitors.

However, this study had several limitations. First, there was no control group and combined anti-diabetic drugs were not fully described. The results can be varied depend on formulation and/or dose of insulin or regimen combined. Also, neither diet nor exercise were evaluated while the participants of this study were receiving treatment. Finally, although this study was designed to eliminate any acute effects of the study drugs, the increase of the insulinogenic index could be influenced by secondary effects of improvement of glucose toxicity for long follow-up period of 6 months. Therefore, direct effect of DPP4 inhibitors on insulin and glucagon levels could be elucidated by well-controlled prospective study using OGTT. It is also expected that a direct comparison with other ethnic groups to show the response of insulin and glucagon in Asian patients will be contributed to understand the effect of DPP4 inhibitors.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619. Article PubMed
2. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008;14:161-168. Article PubMed
3. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708. Article PubMed PDF
4. Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci 2009;337:321-328. PubMed
5. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000;49:975-980. Article PubMed PDF
6. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-2952. Article PubMed
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. Article PubMed PDF
8. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987. Article PubMed PDF
9. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-550. Article PubMed
10. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-496. Article PubMed
11. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106-116. Article PubMed
12. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011;94:217-224. Article PubMed
13. Murai K, Katsuno T, Miyagawa J, Matsuo T, Ochi F, Tokuda M, Kusunoki Y, Miuchi M, Namba M. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. Drugs R D 2014;14:301-308. Article PubMed PMC PDF
14. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-298. Article PubMed
15. Otsuka Y, Yamaguchi S, Furukawa A, Kosuda M, Nakazaki M, Ishihara H. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Endocr J 2015;62:133-143. Article PubMed
16. Rhee EJ, Lee WY, Yoon KH, Yoo SJ, Lee IK, Baik SH, Kim YK, Lee MK, Park KS, Park JY, Cha BS, Lee HW, Min KW, Bae HY, Kim MJ, Kim JA, Kim DK, Kim SW. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:1113-1119. Article PubMed
17. Yang HK, Kang B, Lee SH, Kim HS, Yoon KH, Cha BY, Cho JH. Effects of 6-month sitagliptin treatment on insulin and glucagon responses in Korean patients with type 2 diabetes mellitus. Diabetes Metab J 2015;39:335-341.Article PubMed PMC
18. Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, Yoo JS, Nam JS, Cho MH, Park JS, Ahn CW, Kim KR. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J 2011;35:159-165. Article PubMed PMC
19. Bando Y, Kanehara H, Aoki K, Hisada A, Toya D, Tanaka N. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Investig 2012;3:170-174.Article PubMed
20. Kozawa J, Kitamura T, Nishizawa H, Yasuda T, Maeda N, Otsuki M, Okita K, Iwahashi H, Kaneto H, Funahashi T, Imagawa A, Shimomura I. Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance. J Diabetes Investig 2013;4:190-194.Article PubMed PDF

Figure & Data

References

Citations

Citations to this article as recorded by

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Na
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 545. CrossRef
Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice
Fei Yang, Shan Dang, Hongjun LV, Bingyin Shi
Journal of International Medical Research.2021; 49(1): 030006052098566. CrossRef
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
Rahim Mohammad Naimi, Mark Krogh Hvistendahl, Lise Margrete Thomassen, Hanna Johnsen, Charlotte Bayer Christiansen, Jens Juul Holst, Bolette Hartmann, Palle Bekker Jeppesen
BMJ Open Gastroenterology.2021; 8(1): e000604. CrossRef
Hyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?
Fabrizio Barbetti, Carlo Colombo, Leena Haataja, Corentin Cras-Méneur, Sergio Bernardini, Peter Arvan
Clinical Diabetes and Endocrinology.2016;[Epub] CrossRef

PubReader

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus

Diabetes Metab J. 2015;39(4):304-306. Published online August 17, 2015

DOI: https://doi.org/10.4093/dmj.2015.39.4.304

XML Download

Related articles

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus

About this article

Kim JH. Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus. Diabetes Metab J. 2015;39(4):304-306.

DOI: https://doi.org/10.4093/dmj.2015.39.4.304.

Download citation ↓